The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...

Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...

Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...

PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...

PharPoint Research shaped Medrio CTMS design through early adopter program, influencing clinical trial monitoring workflows ...

Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...

Cecolin 9 shows six-month immunogenicity data in single-dose HPV trial against Gardasil 9, with final results expected in ...

Qutenza meets primary pain endpoint in post-surgical neuropathy trial, showing sustained benefit over ten months in extension ...

EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer, with strong disease control across histology subtypes ...

Atrium Therapeutics doses first patient in ATR-1072 trial for PRKAG2 syndrome, targeting the genetic cause of cardiac disease ...

Enanta dosed its first RESOLVE patient Oct 26. High-risk adult RSV outpatient capacity is already strained, here's what site ...

RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...